Life sciences company Bayer (BAYRY, BAYN.DE) isn't breaking itself up right now.
Bayer CEO Bill Anderson joins 'Squawk on the Street' to discuss why the company hasn't broken up parts of the business, why the current strategy is the best way to go, and more.
Bayer (BAYRY) beats earnings estimates in the fourth quarter of 2023, primarily driven by increased sales of Crop Science and Pharmaceuticals products.
Bayer (BAYRY) acquires exclusive marketing rights for cardiovascular drug acoramidis in Europe from BridgeBio for an upfront payment of $310 million.

Bayer purchases heart drug for up to $310 mln

02:45am, Monday, 04'th Mar 2024
Bayer said on Monday it acquired the exclusive marketing rights for Europe for a new drug that is under regulatory review to treat a rare, potentially fatal heart disease for up to $310 million upfron
BridgeBio Pharma has granted German drugmaker Bayer an exclusive license to commercialize its heart disease drug in Europe, the companies said on Monday.
The Stoxx 600 index will be in the spotlight this week as the European Central Bank (ECB) delivers its second interest rate decision of the year. The index, which tracks the biggest European companies
Bayer is not planning to announce a split of its company at its Capital Markets Day next week, Handelsblatt said on Friday, citing people familiar with the matter.
Bayer said that the head of its consumer health division, Heiko Schipper, would be replaced by Julio Triana, currently the unit's head of commercial operations region international.
Bayer may have to ask shareholders for fresh capital to shore up its finances even after the debt-laden German drugmaker slashed dividends last week in its latest effort to get wiggle room, analysts s
Bayer announced plans to cut its dividend a staggering 95% over the next three years as it looks to recover from debt associated with its acquisition of Monsanto Co., which thrust the German corporati
Bayer (BAYRY) announced plans to cut dividends to pay out only the legally required minimum for three years in the wake of high debt and increasing legal costs.
Shares of Metagenomi Technologies , a genetic medicines company backed by Bayer Healthcare and Moderna , slumped 32% in their Nasdaq debut on Friday.
A U.S. appeals court on Monday refused to dismiss a lawsuit claiming that Bayer AG's Roundup weedkiller caused cancer, the latest setback in the company's efforts to fend off thousands of similar laws
Bayer was ordered to pay $2.25 billion after a Pennsylvania jury unanimously ruled that its Roundup weed killer gave a man cancer.
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE